Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis

Lidija Klampfer1, Laurie-Anne Swaby, Jie Huang

  • 1Albert Einstein Cancer Center, Montefiore Medical Center, Department of Oncology, Bronx, NY 10467, USA. lklampf@aecom.yu.edu

Oncogene
|April 28, 2005
PubMed

Insights

Oncogenic Ras mutations enhance 5-fluorouracil (5-FU) chemotherapy-induced apoptosis in colorectal cancer by downregulating gelsolin, a protein that inhibits cell death. This finding suggests potential therapeutic strategies targeting Ras and gelsolin. Keywords: Ras mutations, 5-FU, colorectal cancer, apoptosis, gelsolin.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cancer Cell Biology

Background:

  • 5-fluorouracil (5-FU) is a cornerstone in colorectal cancer treatment, yet its efficacy is limited by resistance.
  • Understanding the mechanisms of 5-FU resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the role of oncogenic Ras signaling in modulating apoptosis induced by 5-FU in colorectal cancer cells.
  • To elucidate the molecular pathways through which Ras influences 5-FU sensitivity.

Main Methods:

  • Utilized inducible K-RasV12 expression in intestinal epithelial cells and colon cancer cell lines (HCT116, Hke-3).
  • Employed transient transfections, targeted allele deletion, and RNA interference (RNAi) to study gene function.
  • Assessed apoptosis, p53 accumulation and phosphorylation, and expression of apoptosis-related genes (Puma, gelsolin).

Main Results:

  • Oncogenic RasV12 expression promoted 5-FU-induced apoptosis, while WT Ras did not.
  • Ras signaling led to p53 accumulation and phosphorylation, favoring apoptosis over growth arrest.
  • Ras negatively regulated gelsolin expression, an antiapoptotic protein, thereby sensitizing cells to 5-FU.

Conclusions:

  • Ras mutations enhance sensitivity to 5-FU-induced apoptosis, partly via negative regulation of gelsolin.
  • Targeting Ras or overcoming gelsolin's antiapoptotic function may improve 5-FU efficacy in colorectal cancer.

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...